Metformin use by type 2 diabetics is associated with a lower risk of death from cardiovascular disease, according to a recent meta-analysis published in the Archives of Internal Medicine (2008;168:2070-2080).
The meta-analysis of 40 clinical trials, led by Elizabeth Selvin, PhD, MPH, of the Johns Hopkins Bloomberg School of Public Health in Baltimore, found no associations between other diabetes drugs and cardiovascular effects, in part because of insufficient data, the authors noted.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.